No, Paxil (paroxetine) is NOT a monoamine oxidase inhibitor (MAOI)
Paxil is a selective serotonin reuptake inhibitor (SSRI), not an MAOI, and these two drug classes have fundamentally different mechanisms of action. In fact, combining Paxil with MAOIs is absolutely contraindicated due to the life-threatening risk of serotonin syndrome 1.
Mechanism of Action
Paroxetine works by selectively inhibiting the presynaptic reuptake of serotonin, thereby increasing serotonin availability at the synaptic cleft 2, 3. It is one of the most potent and selective serotonin reuptake inhibitors available, with minimal effects on norepinephrine or dopamine reuptake 2, 3.
In contrast, MAOIs work by inhibiting the monoamine oxidase enzyme that breaks down neurotransmitters. Research confirms that paroxetine does not inhibit monoamine oxidase 2. While some in vitro studies have examined paroxetine's effect on MAO enzymes, the concentrations required for any inhibition are in the high micromolar range (IC50 for MAO-A: 265-800 μM), which is far beyond clinically relevant doses 4, 5.
Critical Safety Warning
The concomitant use of Paxil with MAOIs (including linezolid and methylene blue) is absolutely contraindicated 1. This combination can cause severe or fatal serotonin syndrome characterized by:
- Mental status changes (confusion, agitation)
- Neuromuscular hyperactivity (tremors, rigidity, clonus)
- Autonomic instability (fever, tachycardia, blood pressure changes)
- Potentially fatal outcomes 6, 1
Required Washout Periods
When switching between these medication classes 1:
- Do not start Paxil within 2 weeks of stopping an MAOI
- Do not start an MAOI within 2 weeks of stopping Paxil
- These washout periods are mandatory to prevent life-threatening drug interactions
Clinical Classification
The guidelines consistently classify paroxetine as an SSRI alongside other "non-MAOI serotonergic drugs" 6. The 2020 AACAP guidelines explicitly distinguish SSRIs (including paroxetine) from MAOIs (such as phenelzine, isocarboxazid, and moclobemide) when discussing serotonin syndrome risk 6.